Sana Biotechnology, Inc. (($SANA)) announced an update on their ongoing clinical study. Study Overview: Sana Biotechnology, Inc. is conducting a ...

Vir Biotechnology, Inc. (($VIR)) announced an update on their ongoing clinical study. Vir Biotechnology, Inc. is conducting a Phase 1 study titled ...

A new study published in Nature Biotechnology shows that stem cell differentiation is linked to cellular structures called ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

Vir's Phase 2 trial saw 39% and 46% HBsAg loss in doublet and triplet regimens for patients with low baseline HBsAg. 100% of participants in the triplet regimen with HBsAg loss achieved anti-HBs ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can turn ...

Researchers analyzed 11 trials with 655 adults and discovered that taking vitamin D2 supplements decreases the body's vitamin ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

A team of researchers from Tel Aviv University and the Israel Oceanographic and Limnological Research Institute (IOLR) has ...